Estamos no ar no !
Saiba mais
BCEL
Atreca
Deslistada
BCEL foi retirado da bolsa em 18 de março de 2024.
Sobre: Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Funcionários: 90
Notícias
Positivo
Neutro
Negativo
Sentimento
3 meses
Positivo
0%
Neutro
0%
Negativo
0%
Gráficos de preços implementados com Lightweight Charts™